martes, 21 de noviembre de 2017

NGC Update Service: November 20, 2017

NGC Update Service: November 20, 2017



U.S. Food and Drug Administration (FDA) Advisory

November 15, 2017Febuxostat (Brand Name Uloric): FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called allopurinol. FDA required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when the medicine was approved in 2009. Once the final results from the manufacturer are received, FDA will conduct a comprehensive review and will update the public with any new information.

G-I-N NA Co-sponsored Conference

Evidence-Based Clinical Practice Guidelines, Development and Implementation in Mexico, International Forum
When: November 30, 2017 - December 1, 2017
Where: Universidad Nacional Autonoma de Mexico, Postgraduate Unit Auditorium, Mexico
Admission Information & Registration: Contact Jose Luis Mayorga Butron, MD, MSc
View the preliminary program.

Health Awareness Topics: November 2017

How to Participate

Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

No hay comentarios: